NPA Calls for FDA to Use Current Authority to Set Safe Level of Daily Consumption
WASHINGTON – The Natural Products Association (NPA) today rejected new legislation introduced in the U.S. House that would allow CBD products to be used in dietary supplements. The bill, sponsored by Reps. Kurt Schrader (D-Ore.) and Morgan Griffith (R-Va.), fails to set a safe level of daily consumption and would do more to undermine public trust in the safety of supplement products and do nothing to promote public health.
“We support a science-based pathway to allowing CBD in food products, but this is not the right approach and will do more to undermine public trust in the safety of dietary supplements without promoting public health. The Food and Drug Administration already has the authority to regulate CBD products by setting a safe level of daily consumption. Setting a safe level of daily consumption is a better pathway and will do much more than introducing legislation to appease special interests,” said Daniel Fabricant, Ph.D., President and CEO of NPA.
NPA has been the leader in asking the FDA to regulate CBD since 2017, has testified on a number of occasions, and has held several meetings with top FDA officials on the issue. NPA also helped craft legislation passed by the U.S. House of Representatives that provides resources so the FDA can perform a Health Hazard Evaluation (HHE) and set a safe level of CBD for consumers to use each day. The process would follow the same precedent as red yeast rice, which allows a natural product to contain a level of a drug ingredient that the FDA has determined to be safe. With the exception of Epidiolex, all CBD products in the U.S. are considered illegal by the federal government.
